Researchers have pinpointed various drugs typically used to treat diseases such as heart failure and infections that could also be beneficial in treating cancers.
The FDA has granted accelerated approval to linvoseltamab-gcpt, a BCMA-directed bispecific T-cell engager, offering a new option for patients with heavily pretreated relapsed or refractory multiple myeloma....
A new analysis from Western Washington investigators suggests that adverse financial events at diagnosis may delay treatment initiation for patients with hematologic malignancies, highlighting a potential...
The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.
Recent research has identified a molecular pathway associated with cancer-related muscle weakness, a discovery which could help to improved muscle function in patients.
